胸腺肽联合化疗治疗胃癌临床疗效的Meta分析

Meta-analysis of clinical efficiency in treatment of gastric cancer by thymosin combined with chemotherapy

目的系统评价胸腺肽联合化疗与单纯化疗治疗胃癌的临床疗效。方法采用Cochrane系统评价方法,计算机检索中国期刊全文数据库、万方数据库、维普数据库、中国生物医学文献数据库(CBM)、Pub Med、Cochrane图书馆等。纳入含胸腺肽联合化疗治疗胃癌的随机对照试验(RCT)。由2名评价者独立评价并交叉核对纳入研究质量,对纳入的同质研究采用Rev Man5.3进行Meta分析。结果共纳入17篇RCTs,Meta分析结果显示:在提高近期有效率、减轻化疗后呕吐方面,胸腺肽联合化疗优于单纯化疗,差异有统计学意义(均P<0.05)。在改善白细胞减少及神经毒性方面,胸腺肽联合化疗与单纯化疗相比,差异无统计学意义(均P>0.05)。结论胸腺肽联合化疗可提高胃癌近期疗效,对胃癌有一定的辅助治疗作用。

Objective To evaluate the clinical eff icacy of thymosin combined with systematic chemotherapy and chemotherapy alone in the treatment of gastric cancer（GC）.Methods We researched the CNKI, VIP, Wan Fang Database, CBM, Pub Med and Cochrane Library. RCTs about thymosin combined with chemotherapy for gastric cancer were included. 2 reviewers evaluated the quality of included trials independently.The Cochrane Collaborations,software Rev Man 5.3 was used for meta-analysis.Results 17 RCTs were included in the meta-analysis.Results of the meta-analysis showed that thymosin combined with chemotherapy was better than chemotherapy alone in the treatment for GC in improving the short-time efficiency,alleviating the vomiting after chemotherapy and improving the immune fuction. There was statistical significance. There was no statistical significance in diarrhoea,hypoleukia and neurotoxicity between thymosin combined with chemotherapy and chemotherapy alone.Conclusion Thymosin combined with chemotherapy can improve the efficiacy for gastric cancer,reduce the side effect.Thymosin is beneficial to the treatment of GC.